Navigation Links
Hebrew University develops novel approach for treating mitochondrial disorders
Date:6/30/2008

A novel concept for the treatment of mitochondrial disorders using directed enzyme replacement therapy (DERT) has won for a Hebrew University of Jerusalem doctoral candidate one of this year's Kaye Innovation Awards. The awards were presented at this year's 71st meeting of the Hebrew University Board of Governors.

DERT is a therapeutic approach to metabolic disorders whereby the deficient or absent enzyme is artificially manufactured with the addition of a delivery component and is administered to patients on a regular basis.

Mitochondria are special little organelles within the cells (organelles are small, unique structures within the cells that perform specialized tasks). The mitochondria play a critical role - most of the numerous biochemical pathways and reactions are performed within them. However, their most important job is to generate energy out of food and to discard toxic metabolites. (Metabolites are substances produced by a metabolic reaction.)

Inside the mitochondria there are thousands of enzymes that carry out all these reactions. If one of these enzymes is damaged or deficient due to a genetic mutation, a mitochondrial metabolic disorder occurs. Modern medicine offers no cure for mitochondrial disorders (among which are mitochondrial myopathies, maple syrup urine disease and many others). The standard treatment is only palliative, with the aim of improving, postponing or circumventing the massive damage caused by the over- production of free radicals, the accumulation of toxic metabolites and the low rate of energy production.

Matan Rapoport, a Ph.D. student in the Department of Cellular Biochemistry and Human Genetics at the Hebrew University Faculty of Medicine, demonstrated the effectiveness of DERT by treating the mitochondrial disorder lipoamide dehydrogenase (LAD) deficiency. LAD deficiency is an inherited recessive disorder, which results in extensive metabolic disturbances due to a reduction in the activity of the LAD enzyme within the mitochondria.

The clinical course of LAD deficiency is variable, presenting in infancy as a neurological disease of varying severity, or later in life with life-threatening recurrent episodes of liver failure. Most LAD deficiency patients suffer from neurological symptoms.

In developing DERT, Rapoport proposed a novel but simple approach for the delivery of an artificial mitochondrial enzyme directly to its sub-cellular location. The approach is to fuse the manufactured LAD enzyme with a specific delivery component, which will then lead the LAD into the cells and their mitochondria. There, it will substitute for the mutated endogenous enzyme.

For the past four years, Rapoport, under the guidance of Hebrew University Prof. Haya Loberboum-Galski, has been experimenting in vitro on cells taken from patients suffering from LAD deficiency. The results have been highly positive. Experiments are also now being conducted on the in-vivo model of this disorder in LAD-deficient mice. Very promising preliminary results show the ability of this therapy to improve LAD enzymatic activity even in the mouse brain.

Rapoport's invention of enzyme replacement therapy for mitochondrial disorders is patented by Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem. This invention possesses great potential to becoming the treatment of choice for various types of mitochondrial disorders and consequently encompasses a significant commercial potential, as today there is no known medical cure.


'/>"/>

Contact: Rebecca Zeffert
rebeccaz@savion.huji.ac.il
972-025-881-641
The Hebrew University of Jerusalem
Source:Eurekalert

Related biology news :

1. Antioxidant to retard wrinkles discovered by Hebrew University researcher
2. Hebrew SeniorLife researchers search for aging, osteoporosis genes
3. Five young Hebrew University scientists win first competitive EU grants
4. Electronic structure of DNA revealed for 1st time by Hebrew University and collaborating researchers
5. Hebrew University study opening new route for combating viruses
6. A study by the MUHC and McGill University opens a new door to understanding cancer
7. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
8. University of Oregon researcher finds that on waters surface, nitric acid is not so tough
9. Bioengineers at University of Pennsylvania devise nanoscale system to measure cellular forces
10. Binghamton University researchers investigate evolving malaria resistance
11. Society for General Microbiology 161st Meeting, University of Edinburgh
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2016)... -- Securus Technologies, a leading provider of civil and ... and monitoring, announced today that it has offered a ... independent technology judge determine who has the largest and ... calling platform, and the best customer service. ... what we do – which clearly is not the ...
(Date:11/16/2016)... Nov. 16, 2016 Sensory Inc ., ... security for consumer electronics, and VeriTran , ... retail industry, today announced a global partnership that ... to authenticate users of mobile banking and mobile ... software which requires no specialized biometric scanners, ...
(Date:11/14/2016)... Inc. ("xG" or the "Company") (Nasdaq: XGTI, XGTIW), a ... challenging operating environments, announced its results for the third ... conference call to discuss these results on November 15, ... Key Recent Accomplishments The ... Vislink Communication Systems. The purchase is expected to close ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... SAN DIEGO , Dec. 8, 2016 /PRNewswire/ ... presented demonstrating the role of the Breast Cancer ... stage, ER+ breast cancer are most at-risk for ... therapy. Data include results from three studies advancing ... provide information related to tumor biology and inform ...
(Date:12/8/2016)... , December 8, 2016 ... für Molekulargenetik, erweitert seine Palette an anpassbaren SureSeq™ ... Custom FH Panels, das ein schnelles und kostengünstiges ... Das Panel bietet eine Erkennung von Einzel-Nukleotid-Variationen (Single ... mit einem einzigen kleinen Panel und ermöglicht eine ...
(Date:12/8/2016)... San Francisco, CA (PRWEB) , ... December 08, ... ... and Oculus as finalists in the World Technology Awards. uBiome is one of ... were received across all categories. , In addition to uBiome, companies nominated as ...
(Date:12/8/2016)... , Dec. 8, 2016 Savannah ... remediation technologies and selected NewTechBio,s NT-MAX Lake ... microbial based beneficial bacteria, in conjunction with Hexa ... correct deficiencies with National Pollutant Discharge Elimination System ... has experienced a steady history of elevated pH ...
Breaking Biology Technology: